THE MEDICAL AND EPIDEMIOLOGICAL SIGNIFICANCE OF CONDITIONALLY PATHOGENIC MICROORGANISMS AND THE RELEVANCE OF OPTIMIZING CONTROL MEASURES

Millions of individuals have been infected by the COVID-19 pandemic, which has resulted in a public health emergency and a considerable number of fatalities. It is challenging to stop SARS-CoV-2 from spreading throughout the community since it can transfer from person to person through a variety of channels, primarily respiratory droplets. An summary of COVID-19's epidemiology, etiology, clinical presentation, diagnosis, and treatment is given below. Based on the widely held belief that customizing interventions, practices, and/or therapies to each patient's unique clinical, biological, epidemiological, and genetic characteristics would maximize their efficacy and minimize side effects, personalized medicine has been gradually incorporated into a number of diagnostic and therapeutic patient algorithms. Recently, the precision medicine approach's potential advantages have been examined for prospective application in the field of infection prevention and control. The coronavirus has spread quickly due to direct person-to-person respiratory transmission. The present clinical therapy of COVID-19 consists of symptom management, infection prevention and control measures, optimized supportive care, and intensive care support in cases of severe or critical disease because there are currently no clinically established treatment options. Nowadays, creating a successful vaccination is a top scientific focus. The regulatory bodies have already authorized a few vaccines to prevent COVID-19. The opinion examines the information that is currently available and evaluates potential future scenarios in which we might be able to deliver personalized prediction algorithms that identify at-risk patients who should receive customized preventive treatments using sophisticated modeling techniques. To reduce the danger of infection, general prevention and protection measures pertaining to the containment and control of the second or third waves are required. Two vaccines (Pfizer/BioNTech and Moderna) have acquired FDA emergency use permission, and four vaccinations have demonstrated varying efficacies ranging from 62 to 95% thus far. Millions of lives will be saved if these vaccines are distributed effectively and have equitable access in every nation.